51.96
-0.57(-1.09%)
Currency In USD
| Previous Close | 52.53 |
| Open | 51.8 |
| Day High | 54.95 |
| Day Low | 49.93 |
| 52-Week High | 63.06 |
| 52-Week Low | 7.58 |
| Volume | 1.62M |
| Average Volume | 1.59M |
| Market Cap | 2.2B |
| PE | -14.97 |
| EPS | -3.47 |
| Moving Average 50 Days | 51.66 |
| Moving Average 200 Days | 22.82 |
| Change | -0.57 |
If you invested $1000 in Celcuity Inc. (CELC) since IPO date, it would be worth $3,636.11 as of October 19, 2025 at a share price of $51.96. Whereas If you bought $1000 worth of Celcuity Inc. (CELC) shares 5 years ago, it would be worth $9,278.57 as of October 19, 2025 at a share price of $51.96.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Celcuity Provides Update on Status of the PIK3CA Mutated Cohort of Phase 3 VIKTORIA-1 Trial and Releases Additional Data Analysis From Phase 1b Clinical Trial
GlobeNewswire Inc.
Yesterday at 8:30 AM GMT
PIK3CA mutant cohort of the Phase 3 VIKTORIA-1 clinical trial is fully enrolledAdditional analysis of data from a Phase 1b clinical trial that included all patients treated with gedatolisib combined with fulvestrant and palbociclib showed median prog
Detailed Results from PIK3CA Wild-Type Cohort of Phase 3 VIKTORIA-1 Trial Presented at 2025 ESMO Congress Demonstrate Potential for Gedatolisib Regimens to be Practice Changing for Patients with HR+/HER2- Advanced Breast Cancer
GlobeNewswire Inc.
Yesterday at 8:30 AM GMT
Clinical benefit of the gedatolisib regimens was consistent across patient subgroups Hyperglycemia was reported in only 9.2% of patients treated with gedatolisib + palbociclib + fulvestrant (“gedatolisib triplet”) and in 11.5% of patients treated wit
Celcuity Presents Updated Data at the 2025 ESMO Congress from Phase 1 Study Evaluating Gedatolisib Plus Darolutamide in Men with Metastatic Castration Resistant Prostate Cancer (“mCRPC”)
GlobeNewswire Inc.
Yesterday at 8:30 AM GMT
Median radiographic progression free survival (“rPFS”) was 9.1 months and the six-month rPFS rate was 67% No patients discontinued study treatment due to a treatment-related adverse event (“TRAE”) MINNEAPOLIS, Oct. 18, 2025 (GLOBE NEWSWIRE) -- Celc